Rock Lab
Our Research
Mycobacterium tuberculosis (Mtb) is the leading cause of death from an infectious disease. The Rock lab investigates the mechanisms that enable this bacterium to cause disease and evade antibiotics, aiming to lay the groundwork for new therapies to better control this global pandemic.
Host-pathogen interactions. A defining feature of Mtb’s pathogenicity is its ability to chronically infect an immune competent host for years. The physiological adaptations that allow Mtb to withstand a robust immune response and maintain long-term infection also confer antibiotic tolerance. Despite its central importance in Mtb’s lifecycle, the molecular basis of chronic infection remains poorly understood. The Rock lab is developing new functional genomic approaches to uncover the mechanisms that enable Mtb persistence.
​
​Bug-drug interactions. TB can be treated with antibiotics. However, TB treatment requires a combination of four drugs taken for 4-6 months. This lengthy treatment regimen is one of the most important roadblocks to effective TB control. Why is TB so difficult to treat? While the answer is multifactorial, one major difficulty is the resistance of the infecting bacterium– both intrinsic and acquired– to many distinct classes of antimicrobials. Beyond resistance, antibiotic tolerant bacteria arise during infection, further complicating treatment. The Rock lab investigates the molecular mechanisms of antibiotic tolerance and resistance in Mtb.
​
​NTMs. Non-tuberculous mycobacteria (NTM) like M. abscessus and M. avium are increasingly problematic pathogens. These bacteria cause skin and soft tissue infections and are a common opportunistic pathogen of the lung in patients with underlying pulmonary dysfunction, including cystic fibrosis. NTM infections can be exceedingly difficult to treat. The Rock lab leverages chemical-genomic approaches to understand mechanisms of antibiotic resistance in NTMs, knowledge which can then be used to facilitate development of new drugs to treat these infections.
